Table 4 Clinicopathological factors of STZ based treated-19 patients associated with MGMT expression levels.
Clinicopathological factor (n = 19) | MGMT-positive (n = 10) | MGMT-negative (n = 9) | p value |
|---|---|---|---|
Clinical factor | |||
Age, years, median (range) | 46 (27–65) | 55 (40–75) | 0.21 |
Sex, male | 3 | 6 | 0.13 |
Genetic syndrome | |||
MEN type 1 | 0 | 0 | – |
VHL | 0 | 0 | – |
Tumor factor | |||
Tumor size, mean ± SD, mm | 55.7 ± 34.2 | 56.2 ± 20.7 | 0.6 |
Ki-67 index, mean ± SD | 16.4 ± 8.9 | 12.5 ± 8.7 | 0.4 |
Mitosis, 10 HPF, mean ± SD | 5.4 ± 6.8 | 3.3 ± 3.4 | 0.78 |
Chromogranin A positive | 6 | 7 | 0.63 |
Synaptophysin positive | 9 | 9 | 0.53 |
CD-56 positive | 9 | 8 | 0.74 |
Lymph node metastasis | 4 | 3 | 0.57 |
Liver metastasis | 9 | 8 | 0.94 |
Synchronous | 6 | 7 | 0.37 |
Metachronous | 3 | 1 | 0.31 |
Functionality, nonfunctioning | 9 | 8 | 0.74 |
Tumor grade | |||
NET-G2 | 6 | 9 | 0.054 |
NET-G3 | 4 | 0 | |
